Repligen to Report First Quarter 2019 Financial Results
May 02 2019 - 2:20PM
Repligen Corporation (NASDAQ:RGEN) today announced that the Company
will report its first quarter 2019 financial results on Thursday,
May 9, 2019. The Company will issue a press release before the
market opens and will host a conference call at 8:30 a.m. EDT to
discuss business updates and financial results for the three-month
reporting period ended March 31, 2019.
The conference call will be accessible by dialing toll-free
(866) 777-2509 for domestic callers and (412) 317-5413 for
international callers. No passcode is required for the live call.
In addition, a webcast will be accessible via the Investor
Relations section of the Company’s website. Both the conference
call and webcast will be archived for a period of time following
the live event. The replay dial-in numbers are (877) 344-7529 for
callers in the U.S., (855) 669-9658 for callers in Canada and (412)
317-0088 for international callers. Replay listeners must provide
the passcode 10131193.
About Repligen Corporation Repligen Corporation
(NASDAQ:RGEN) is a global bioprocessing company that develops and
commercializes highly innovative products that deliver cost and
process efficiencies to biological drug manufacturers worldwide.
Our portfolio includes filtration products (including XCell™ ATF,
TangenX™ SIUS™ TFF and Spectrum KrosFlo™ TFF filters and systems),
chromatography products (OPUS® pre-packed columns, chromatography
resins, ELISA kits) and protein products (Protein A affinity
ligands including NGL Impact®-A, cell culture growth factors). Our
XCell™ ATF Systems, available in stainless steel and single-use
configurations, are used in perfusion processes to continuously
concentrate cells and increase product yield from a bioreactor.
Single-use SIUS™ TFF cassettes and hardware are used for biologic
drug concentration in downstream filtration processes. KrosFlo™ TFF
cartridges and systems are used in both upstream and downstream
filtration processes. Our innovative line of OPUS® chromatography
columns, used in bench-scale through commercial-scale biologics
purification, are delivered pre-packed to our customers with their
choice of affinity resin. Protein A ligands and growth factor
products that we produce are essential components of Protein A
affinity resins used in biologics purification, and cell culture
media used to accelerate cell growth in a bioreactor. Repligen’s
corporate headquarters are in Waltham, MA (USA), with additional
administrative and manufacturing operations in Marlborough, MA,
Rancho Dominguez, CA, Lund, Sweden and Ravensburg, Germany.
This press release may contain forward-looking
statements within the meaning of the federal securities laws.
Investors are cautioned that statements in this press release which
are not strictly historical statements including, without
limitation, statements identified by words like “believe,”
“expect,” “may,” “will,” “should,” “seek,” or “could” and similar
expressions, constitute forward-looking statements. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those anticipated, including risks discussed from time to time
in our filings with the Securities and Exchange Commission. We
expressly disclaim any responsibility to update any forward-looking
statements, except as required by law.
Repligen Contact:Sondra S. NewmanSenior
Director Investor Relations(781) 419-1881investors@repligen.com
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024